<DOC>
	<DOCNO>NCT01217398</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving temozolomide together bevacizumab may kill tumor cell . PURPOSE : This phase II trial study give temozolomide together bevacizumab see well work treat patient metastatic melanoma eye .</brief_summary>
	<brief_title>Temozolomide Bevacizumab Treating Patients With Metastatic Melanoma Eye</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate efficacy temozolomide combination bevacizumab treat patient metastatic uveal melanoma amenable curative surgery . Secondary - To determine response rate patient . - To determine duration response patient . - To determine progression-free survival patient . - To determine overall survival patient . - To determine safety treatment regimen patient . - To study CT perfusion image functional imaging response patient . - To determine pharmacogenetic influence constitutional VEGF-A polymorphism efficacy toxicity bevacizumab . ( ancillary ) OUTLINE : Patients receive oral temozolomide daily day 1-7 15-21 bevacizumab IV 30-90 minute day 8 22 . Treatment repeat every 28 day 6 course . Patients achieve least stable disease receive bevacizumab monotherapy IV every 2 week maintenance therapy absence unacceptable toxicity disease progression . Patients undergo CT perfusion image baseline , day 28 , 3 6 month . Blood sample collect baseline periodically VEGF-A genetic polymorphism analysis . After completion study treatment , patient follow 1 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm uveal melanoma Metastatic disease Measurable disease , define ≥ 1 measurable lesion measure RECIST criterion No curative surgical treatment envisage No active brain metastasis ( clinical suspicion , must brain CT scan within 28 day ) PATIENT CHARACTERISTICS : WHO performance status ( PS ) 01 OR Karnofsky PS 70100 % Life expectancy ≥ 12 week Hemoglobin ≥ 10 g/dL Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) OR calculate creatinine clearance ≥ 50 mL/min Proteinuria &lt; 2+ urinary dipstick OR 24hour proteinuria ≤ 1 g Total bilirubin ≤ 1.5 time ULN AST/ALT ≤ 2.5 time ULN Lactate dehydrogenase ≤ 5 time ULN INR PT ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study treatment No uncontrolled active disease risk bleeding , ongoing infection , clot disorder No cancer except skin carcinoma cervical carcinoma situ No preexist peripheral neuropathy , &gt; grade 2 ( NCI CTCAE ) No failure comply medical followup study geographical , social , psychological reason No recent thrombophlebitis pulmonary embolism within past 6 month No uncontrolled hypertension ( systolic BP &gt; 150 mm Hg and/or diastolic BP &gt; 100 mm Hg ) No concurrent active cardiovascular disease , uncontrolled medical treatment within past 6 month , include follow : Unstable angina Severe hypertension Severe arrhythmia No unhealed wound , active peptic ulcer , bone fracture , history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month No know hypersensitivity bevacizumab , temozolomide , excipients PRIOR CONCURRENT THERAPY : No prior chemotherapy metastatic disease At least 24 hour since insertion central infusion port More 5 day since prior nonhepatic biopsy aspiration cytology More 10 day since prior aspirin ( &gt; 325 mg/day ) , clopidogrel ( &gt; 75 mg/day ) , fulldose oral parenteral anticoagulant therapy , except prophylactic anticoagulant therapy prior inclusion study More 14 day since prior laparoscopic liver biopsy More 28 day since prior major surgery More 28 day since prior participation another study experimental treatment No concurrent anticancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>ciliary body choroid melanoma , small size</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>metastatic intraocular melanoma</keyword>
	<keyword>stage IV intraocular melanoma</keyword>
</DOC>